Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

But what if one of them encounters significant competition soon? That's what some investors believe might happen, given ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...

After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...

Biotech stocks are gaining momentum on M&A activity, cancer drug launches and upcoming autoimmune treatment data.

FDA drug approvals are reshaping biotech stocks—track key decisions, FDA leadership turmoil, and volatility. Click for a look ...

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrie ...

Sara Ahmed ’26, a student in the MBA for Executives program, drew on her background in biotech to craft a speaker series ...